Travere Therapeutics overcame a challenging development path to win FDA approval for Filspari (sparsentan) as the first-ever treatment for focal segmental glomerulosclerosis (FSGS), a rare and progressive kidney disease. The journey was far from smooth—highlighted by a Phase 3 trial setback in the DUPLEX study, which failed to meet its primary endpoint measuring kidney function decline. Despite this, the drug demonstrated meaningful reductions in proteinuria, a key marker of disease progression, which ultimately supported its case with regulators. The FDA also extended its review timeline to further assess the data, underscoring the uncertainty surrounding the approval.

The approval marks a major milestone for both patients and the life sciences industry, as FSGS previously had no FDA-approved therapies. Filspari is now positioned to address a significant unmet need, with tens of thousands of eligible patients in the U.S. and strong commercial potential. The decision highlights the FDA’s willingness to weigh broader clinical benefits—even amid imperfect trial outcomes—especially in rare diseases where treatment options are limited.

Click here to read the entire article.